Wednesday, October 04, 2023 The MA41 study: De-Escalation of adjuvant ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO) has closed to accrual. The sponsors Breast International Group and Institut Jules Bordet have decided to close the recruitment of this trial. For more information please visit the MA41 members trial page.
